Therapeutic effects of mifepristone combined withGestrinone on patients with endometriosis

Abstract

Objective:To evaluate the clinical therapeutic effects of mifepristone combined with gestrinone on patients with endometriosis.Methods:A total of 150 endometriotic patients treated in our hospital between January 2014 and December 2015 were randomly divided into a control group and a treatment group (n=75). The control group began to orally take gestrinone capsules on the second day after menstruation started (2.5 mg/time, twice/week). The treatment group orally took mifepristone tablets (12.5 mg/time, once/day), and the dosage and administration of gestrinone capsules were the same as those of the control group. After 24 weeks of consecutive treatment, the clinical therapeutic effects of the two groups were assessed, and the pelvic symptom score, clinical sign score, serum sex hormone levels and pregnancy outcomes were compared.Results:The total effective rates of control and treatment groups were 77.3% and 90.7% respectively, between which the difference was statistically significant (P<0.05). After treatment, the scores of pelvic symptoms (dysmenorrhea, dyspareunia, pelvic pain) and clinical signs (pelvic tenderness, induration) significantly reduced (P<0.05). Each score of the treatment group decreased more significantly than that of the control group did (P<0.05). The serum follicle hormone, luteinizing hormone, estrogen and progesterone levels were significantly lower than those before treatment (P<0.05). Each level of the treatment group dropped more significantly than that of the control group did (P<0.05). The pregnancy rates in the 6th and 12th months of follow-up were 28.0% and 13.3% in the control group respectively, and 42.7% and 29.3% in the treatment group respectively. Such rates of the two groups were significantly different at each follow-up time point (P<0.05).Conclusion:Mifepristone combined with gestrinone had satisfactory clinical therapeutic effects on endometriosis by reducing hormone levels and improving pregnancy outcomes. Therefore, this regimen is worthy of promotion and application in clinical practice.

The new application of mifepristone in the relief of adenomyosis-caused dysmenorrhea

“…Our data showed that mifepristone significantly decreased platelet count in serum of the adenomyosis patients. Therefore, the clinical results further proved that mifepristone was efficient in the treatment of adenomyosis-associated dysmenorrhea and the effect of treatment in adenomyosis is similar to endometriosis [40,41].…”

Cai's Neiyi Prescription promotes apoptosis and inhibits inflammation in endometrial stromal cells with endometriosis through inhibiting USP10

“…Currently, drug and surgery are the main therapeutic strategies for EM caused infertility; although the surgery can reduce the pain, it also leads to infertility because of surgical trauma and easy relapse . Treatment of EM using TCM is routine and demonstrates the function of promoting fertility, alleviating pain, and preventing relapse.…”

Endometriosis - Review Of Current Therapeutic Aproaches For Disease Control

“…Резултатите показват подобряване на симптомите при жените, приемащи мифепристон от 5 мг и 10 мг, сравнено с тези, приемащи мифепристон 2,5 мг и плацебо. Друго проучване, включващо 150 жени с ендометриоза, разделени в две групи -едната приемаща гестринон, а другата комбинация от мифепристон и гестринон в продължение на 24 седмици, показва по-добро повлияване на дисменореята, диспареунията и тазовата болка при комбинираното лечение (71).…”